Clinical trials: Calcitonin
Migraine, Episodic Migraine
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
- Conditions
- Migraine, Episodic Migraine, Headache, Headache, Migraine
- Trial name
- NCT06004388
- Testing
- Click Digital Therapeutic
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Click Therapeutics, Inc.
Health Postmenopausal Women
Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide).
This study will assess the effect of concomitant antacid on the pharmacokinetics and pharmacodynamics of SMC021
- Trial name
- NCT00421590
- Testing
- SMC021
- Where
- Denmark
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Novartis
Obese Adults
A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities
This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of VK3019 in overweight and obese adults without…
- Trial name
- NCT07846033
- Testing
- SC VK3019
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Viking Therapeutics, Inc.
Migraine
Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)
The purpose of this study is to determine the receptor occupancy (RO) associated with telcagepant (MK-0974) administration based on displacement of [11C]MK-4232 from the CGRP receptors in the brain using PET.
- Trial name
- NCT01315847
- Testing
- telcagepant, [11C]MK-4232
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Episodic Migraine
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients
This study is to evaluate the efficacy and safety of AMG334 in adult patients with episodic migraine
- Trial name
- EMPOwER (NCT03333109)
- Testing
- Erenumab
- Where
- 81 sites in Argentina, India and 9 more
- Volunteers
- 900 people
- Sponsor
- Novartis Pharmaceuticals
Angina Pectoris, Coronary Heart Disease
A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)
This study will assess the safety of telcagepant in coronary artery disease (CAD) participants with stable angina during exercise treadmill testing and evaluate whether calcitonin gene-related peptide (CGRP) receptor antagonism…
- Conditions
- Angina Pectoris, Coronary Heart Disease, Calcitonin Gene-related Peptide Receptor
- Trial name
- NCT01294709
- Testing
- telcagepant
- Volunteers
- 64 people
- Sponsor
- Merck Sharp & Dohme LLC
Dry Eye, Asthenopia
Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia
Safety and Efficacy of Medications for Migraine in Patients with Dry Eye Disease or Asthenopia
- Trial name
- NCT05895500
- Testing
- Injection for SC administration (120mg/syringe), Tablet (50mg/tablet), oral
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Nvision Laser Eye Centers
Osteopenia
A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis
The primary purpose of this study was to evaluate the efficacy of oral calcitonin (rsCT)tablets in the prevention of bone loss in postmenopausal women with lower bone mineral density at increased risk of fracture.
- Trial name
- NCT01292187
- Testing
- Oral calcitonin at dinnertime, Oral calcitonin at bedtime
- Where
- 10 sites in United States
- Volunteers
- 129 people
- Sponsor
- Tarsa Therapeutics, Inc.
Osteoarthritis
Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)
The purpose of this phase III study is to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Patients with Osteoarthritis of the Knee
- Trial name
- NCT00704847
- Testing
- Oral Salmon Calcitonin
- Where
- 18 sites in United States, Belgium and 8 more
- Volunteers
- 1,030 people
- Sponsor
- Nordic Bioscience A/S
Osteoarthritis
SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study
The purpose of this study is to expose patients with OA to calcitonin and to determine plasma calcitonin levels after administration of 0.6 mg and 0.8 mg oral calcitonin.
- Trial name
- NCT00486369
- Testing
- Oral salmon calcitonin
- Where
- Denmark
- Sponsor
- Nordic Bioscience A/S
Forearm Fracture
Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women
Calcitonin has been used for many years for treating osteoporosis in postmenopausal women, and it has been shown that calcitonin reduces pain after spine and hip fracture in women with osteoporosis.
- Trial name
- NCT00239889
- Testing
- Salmon calcitonin
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 300 people
- Sponsor
- Novartis
Postmenopausal Osteoporosis
Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women
This is a phase I study to analyze bioavailability and pharmacodynamic of two different variants of oral salmon calcitonin (SMC021) in postmenopausal women
- Trial name
- NCT00411125
- Testing
- Oral salmon calcitonin
- Where
- Denmark
- Volunteers
- 86 people
- Sponsor
- Novartis
Osteoarthritis
Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis
The purpose of this Phase III study is to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of patients with osteoarthritis of the knee.
- Trial name
- NCT00486434
- Testing
- SMC021 Oral Calcitonin
- Where
- 9 sites in Czechia, Denmark and 4 more
- Volunteers
- 1,176 people
- Sponsor
- Nordic Bioscience A/S
Osteoporosis, Post-Menopausal
PTH Comparison in Post Menopausal Women
Compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.
- Trial name
- NCT00543218
- Testing
- teriparatide 20 micrograms/day subcutaneous, calcitonin 100 IU/day subcutaneous
- Where
- 4 sites in Taiwan
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women
This is a phase I study to analyze the effect of water and food intake on the bioavailability and pharmacodynamic of oral salmon calcitonin (SMC021) and salmon calcitonin nasal spray in post-menopausal women.
- Trial name
- NCT00395395
- Testing
- Oral salmon calcitonin, salmon calcitonin nasal spray
- Where
- Denmark
- Volunteers
- 56 people
- Sponsor
- Novartis
Osteoporosis
A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).
- Trial name
- NCT00620854
- Testing
- Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tarsa Therapeutics, Inc.
Osteoporosis, Postmenopausal
A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women
The purpose of this study is to compare the effectiveness and tolerability of two medications, calcitonin nasal spray and a tablet containing calcitonin, in postmenopausal women with osteoporosis.
- Trial name
- ORACAL (NCT00959764)
- Testing
- Oral Calcitonin Tablets, Intranasal Calcitonin
- Where
- 20 sites in United States, Bulgaria and 4 more
- Volunteers
- 565 people
- Sponsor
- Tarsa Therapeutics, Inc.
Osteoporosis, Postmenopausal
Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis
To compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.
- Trial name
- NCT00542984
- Testing
- teriparatide 20 micrograms/day subcutaneous, salmon calcitonin 100 IU/day subcutaneous
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Migraine
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could…
- Trial name
- HER-MES (NCT03828539)
- Testing
- Erenumab, Topiramate
- Where
- 79 sites in Germany
- Volunteers
- 777 people
- Sponsor
- Novartis Pharmaceuticals
Phase 1 Pharmacodynamic Study
A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women
This study is being conducted to assess the plasma CTx-1 concentrations when dosing is at night and to compare these results with those obtained with a placebo control and with commercially available nasal calcitonin.
- Trial name
- NCT00803686
- Testing
- Oral rsCT tablet, Fortical (rsCT) nasal spray
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Tarsa Therapeutics, Inc.